Zacks Research Issues Pessimistic Estimate for PCRX Earnings

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Research analysts at Zacks Research cut their Q1 2026 earnings per share estimates for Pacira BioSciences in a research note issued on Tuesday, October 15th. Zacks Research analyst R. Department now anticipates that the company will earn $0.73 per share for the quarter, down from their prior estimate of $0.81. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.24 per share. Zacks Research also issued estimates for Pacira BioSciences’ Q2 2026 earnings at $0.77 EPS, Q3 2026 earnings at $0.84 EPS and FY2026 earnings at $3.37 EPS.

A number of other brokerages have also commented on PCRX. Raymond James lowered shares of Pacira BioSciences from an “outperform” rating to a “market perform” rating in a research note on Monday, August 12th. Truist Financial downgraded shares of Pacira BioSciences from a “buy” rating to a “sell” rating and cut their target price for the stock from $30.00 to $8.00 in a research report on Tuesday, August 13th. Needham & Company LLC lowered their price target on Pacira BioSciences from $43.00 to $22.00 and set a “buy” rating on the stock in a report on Monday, August 12th. Jefferies Financial Group raised their price target on Pacira BioSciences from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday, September 24th. Finally, Royal Bank of Canada increased their target price on Pacira BioSciences from $14.00 to $15.00 and gave the company a “sector perform” rating in a report on Friday, October 4th. Two analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $24.20.

Pacira BioSciences Price Performance

Shares of NASDAQ:PCRX opened at $16.95 on Thursday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 5.70 and a current ratio of 6.82. The firm has a market cap of $788.95 million, a price-to-earnings ratio of 11.85 and a beta of 0.84. The business has a 50-day simple moving average of $14.53 and a two-hundred day simple moving average of $22.16. Pacira BioSciences has a fifty-two week low of $11.16 and a fifty-two week high of $35.95.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings results on Tuesday, July 30th. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.53 by $0.11. Pacira BioSciences had a net margin of 9.21% and a return on equity of 13.22%. The company had revenue of $178.02 million during the quarter, compared to the consensus estimate of $173.31 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. GAMMA Investing LLC raised its stake in Pacira BioSciences by 229.6% during the second quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock valued at $38,000 after purchasing an additional 932 shares in the last quarter. Park Place Capital Corp bought a new stake in shares of Pacira BioSciences in the 2nd quarter valued at approximately $46,000. Innealta Capital LLC purchased a new position in shares of Pacira BioSciences in the 2nd quarter worth approximately $50,000. nVerses Capital LLC increased its position in shares of Pacira BioSciences by 800.0% during the 2nd quarter. nVerses Capital LLC now owns 1,800 shares of the company’s stock valued at $51,000 after purchasing an additional 1,600 shares during the last quarter. Finally, Natixis bought a new position in shares of Pacira BioSciences during the 1st quarter valued at approximately $95,000. 99.73% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Pacira BioSciences

In other Pacira BioSciences news, CEO Frank D. Lee bought 8,264 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The stock was purchased at an average price of $12.10 per share, for a total transaction of $99,994.40. Following the completion of the transaction, the chief executive officer now owns 107,784 shares of the company’s stock, valued at $1,304,186.40. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have acquired a total of 11,176 shares of company stock valued at $136,240 over the last ninety days. 6.40% of the stock is currently owned by company insiders.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.